Cellexus Biosystems appoints Dr Julie Bick as its US-based Chief Scientific Officer
Cellexus Biosystems PLC announced that it has appointed Dr Julie Bick as its Chief Scientific Officer. Dr Bick has the world-wide responsibility for leading the Company's research and customer support programmes and will be based in the US from its wholly own subsidiary, Cellexus Biosystems Inc..
Dr Bick is a biochemist with expertise in cell culture and has worked in the areas of protein therapeutics, protein engineering and assay platform development. Prior to joining Cellexus Biosystems, Dr Bick was a Senior Scientist (group leader) at Sanofi-Aventis in New Jersey where she was responsible for development protein expression systems (bacterial, yeast and mammalian cell lines), for the large-scale production of pharmaceutically relevant proteins and the generation of transgenic human tissue culture cells for the analysis of protein-protein interactions.
Dr Bick has also held research positions at: UT South Western Medical Centre (Dallas, TX), Syngenta, Torrey Mesa Research Institute (San Diego, CA), AgBiotech Centre, Rutgers University (NJ), and has a Ph.D from Southampton University (United Kingdom).
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Urinary tract infection: How bacteria nestle in

Cell atlas of the aging lung

New Chance for Better Pandemic Response - Researchers succeed in developing neutralizing anti-SARS-CoV-2 antibodies from immune cells of healthy donors

Link between bacteria metabolism and communication could pave way for new antivirulence drugs

Merck Confirms Guidance for 2022 and Delivers Strong Organic Growth in Q3 - Merck continued to grow despite a challenging external operating environment
New tool illuminates connections between stem cells and cancer
